Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)

Authors: Lee, Chee Khoon ^a, Liao, Bin-Chi ^{b, c, ∗}, Subramaniam, Shalini ^a, Chiu, Chao-Hua ^d, Mersiades, Antony J. ^a, Ho, Chao-Chi ^b, Brown, Chris ^a, Lai, Chun-Liang ^e, Hughes, Brett G.M. ^{f, g}, Yang, Tsung-Ying ^h, O’Byrne, Ken ⁱ, Luo, Yung-Hung ^j, Yip, Sonia ^a, Ho, Ching-Liang ^k, Bray, Victoria ^l, Su, Wu-Chou ^m, Moore, Melissa ⁿ, Feng, Wei-Lien ^o, Bai, Ya-Ying ^b, Ford, Kate ^a, Cummins, Michelle M. ^a, Stockler, Martin R. ^a, Solomon, Benjamin J. ^p, John, Thomas ^p, Chih-Hsin Yang, James ^{b, c}

Source: In JTO Clinical and Research Reports February 2025 6(2)

Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations

Authors: Wang, Mengzhao ^a, Xu, Yan ^a, Huang, Wen-Tsung ^b, Su, Wu-Chou ^c, Gao, Bo ^d, Lee, Chee Khoon ^e, Fang, Jian ^f, Zhu, Xuehua ^g, Yang, Zhenfan ^g, Jänne, Pasi A. ^h, Yang, James Chih-Hsin ^{i, ⁎}

Source: In Lung Cancer January 2025 199

Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study

Authors: Chan, Chang-Chuan, Chan, Si-Wa, Chang, I-Shou, Chang, Jer-Hwa, Chao, Kun-San, Chen, Chi-Jen, Chen, Huei-Wen, Chiang, Chun-Ju, Chiou, Hung-Yi, Chou, Mei-Chun, Chung, Chi-Li, Chung, Ta-Jung, Guo, Yue Leon, Hsiao, Chin-Fu, Huang, Chien-Sheng, Ko, Sheung-Fat, Lee, Mei-Hsuan, Li, Yao-Jen, Liao, Yu-San, Lu, Yueh-Hsun, Ou, Hsin-You, Wu, Ping-An, Yang, Hwai-I, Yang, Shi-Yi, Yang, Szu-Chun, Chang, Gee-Chen ^*, Chiu, Chao-Hua ^*, Yu, Chong-Jen ^*, Chang, Yeun-Chung, Chang, Ya-Hsuan, Hsu, Kuo-Hsuan, Wu, Yu-Chung, Chen, Chih-Yi, Hsu, Hsian-He, Wu, Ming-Ting, Yang, Cheng-Ta, Chong, Inn-Wen, Lin, Yu-Ching, Hsia, Te-Chun, Lin, Meng-Chih, Su, Wu-Chou, Lin, Chih-Bin, Lee, Kang-Yun, Wei, Yu-Feng, Lan, Gong-Yau, Chan, Wing P, Wang, Kao-Lun, Wu, Mei-Han, Tsai, Hao-Hung, Chian, Chih-Feng, Lai, Ruay-Sheng, Shih, Jin-Yuan, Wang, Chi-Liang, Hsu, Jui-Sheng, Chen, Kun-Chieh, Chen, Chun-Ku, Hsia, Jiun-Yi, Peng, Chung-Kan, Tang, En-Kuei, Hsu, Chia-Lin, Chou, Teh-Ying, Shen, Wei-Chih, Tsai, Ying-Huang, Tsai, Chun-Ming, Chen, Yuh-Min, Lee, Yu-Chin, Chen, Hsuan-Yu, Yu, Sung-Liang, Chen, Chien-Jen, Wan, Yung-Liang, Hsiung, Chao Agnes, Yang, Pan-Chyr ^*

Source: In The Lancet Respiratory Medicine February 2024 12(2):141-152

Clinical practice consensus for the diagnosis and management of melanoma in Taiwan

Authors: Wu, Chiao-En, Liao, Yi-Hua, Wu, Cheng-Lin, Yen, Ruoh-Fang, Lin, Chia-Chi, Yang, Muh-Hwa, Yen, Chueh-Chuan, Su, Wu-Chou, Yen, Chia-Jui, Chang, Yi-Fang, Wu, Ming-Fang, Yang, Youngsen, Lin, Chen-Yuan, Yang, Wen-Chi, Wang, Hui-Ching, Li, Cheng-Yuan, Ho, Yin-Yu, Chang, Yao-Yu, Wu, Chieh-Shan, Hsu, Hsiu-Cheng, Chen, Kuang-Hua, Huang, Yenlin, Chen, Chih-Jung, Chuang, Pei-Ju, Lai, Yung-Chi, Huang, Yu-Yi, Tseng, Neng-Chuan, Huang, Yi-Ting, Chu, Chia-Yu, Wen-Cheng Chang, John

Source: In Journal of the Formosan Medical Association January 2024 123(1):7-15

Cost‐effectiveness of first‐line immunotherapies for advanced non‐small cell lung cancer

Authors: Yang, Szu‐Chun, Ou, Huang‐Tz, Su, Wu‐Chou, Wang, Shi‐Yi

Source: Cancer medicine. 12(7):8838-8850

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100187356615.0x000001&indx=1&recIds=ETOCvdc_100187356615.0x000001

Concise nanotherapeutic modality for cancer involving graphene oxide dots in conjunction with ascorbic acidElectronic supplementary information (ESI) available: Chemical structures of H2Asc derivatives; chemical properties of NGODs; H2O2 production in the presence of high concentrations of H2Asc; the EPR spectrum of the TEMPO-OH standard; HPLC spectra of NGODs–H2Asc solutions; biocompatibility of NGODs; quantification of GSH depletion; electronic band levels of NGOD determination. See DOI: https://doi.org/10.1039/d3nr00431g

Authors: Shih, Chun-Yan, Wang, Pei-Ting, Chung, Wei-Pang, Wang, Wen-Hsiu, Chiang, I-Ting, Su, Wu-Chou, Huang, Wei-Lun, Teng, Hsisheng

Source: Nanoscale. 15(24):10232-10243

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185814991.0x000001&indx=1&recIds=ETOCvdc_100185814991.0x000001

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

Authors: Camidge, D. Ross, Barlesi, Fabrice, Goldman, Jonathan W., Morgensztern, Daniel, Heist, Rebecca, Vokes, Everett, Spira, Alex, Angevin, Eric, Su, Wu-Chou, Hong, David S., Strickler, John H., Motwani, Monica, Dunbar, Martin, Parikh, Apurvasena, Noon, Elysa, Blot, Vincent, Wu, Jun, Kelly, Karen

Source: Journal of clinical oncology. 41(5):1105-1115

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100181430078.0x000001&indx=1&recIds=ETOCvdc_100181430078.0x000001

Low-Dose Computed Tomography Screening in Relatives With a Family History of Lung Cancer

Authors: Wang, Chi-Liang, Hsu, Kuo-Hsuan, Chang, Ya-Hsuan, Ho, Chao-Chi, Chiang, Chun-Ju, Chen, Kun-Chieh, Cheung, Yun-Chung, Huang, Pei-Ching, Chen, Yu-Ruei, Chen, Chih-Yi, Hsu, Chung-Ping, Hsia, Jiun-Yi, Chen, Hsuan-Yu, Yang, Shi-Yi, Li, Yao-Jen, Yang, Tsung-Ying, Tseng, Jeng-Sen, Chuang, Cheng-Yen, Hsiung, Chao A., Chen, Yuh-Min, Huang, Ming-Shyan, Yu, Chong-Jen, Chen, Kuan-Yu, Su, Wu-Chou, Chen, Jeremy J.W., Yu, Sung-Liang, Chen, Chien-Jen, Yang, Pan-Chyr, Tsai, Ying-Huang, Chang, Gee-Chen

Source: In Journal of Thoracic Oncology November 2023 18(11):1492-1503

Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial

Authors: John, Thomas, Grohé, Christian, Goldman, Jonathan W., Shepherd, Frances A., de Marinis, Filippo, Kato, Terufumi, Wang, Qun, Su, Wu-Chou, Choi, Jin Hyuk, Sriuranpong, Virote, Melotti, Barbara, Fidler, Mary J., Chen, Jun, Albayaty, Muna, Stachowiak, Marta, Taggart, Sarah, Wu, Yi-Long, Tsuboi, Masahiro, Herbst, Roy S., Majem, Margarita

Source: In Journal of Thoracic Oncology September 2023 18(9):1209-1221

Zero-valent iron based nanoparticles selectively inhibit cancerous cells through mitochondria-mediated autophagy

Authors: Shieh, Dar-Bin, Yang, Li-Xing, Lee, Wei-Ting, Huang, Kuang Jing, Wu, Ya-Na, Su, Wu-Chou, Chen, Don-Hwang, Tsang, Benjamin

Source: 2017 IEEE 17th International Conference on Nanotechnology (IEEE-NANO) Nanotechnology (IEEE-NANO), 2017 IEEE 17th International Conference on. :168-170 Jul, 2017

Relation: 2017 IEEE 17th International Conference on Nanotechnology (IEEE-NANO)

Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC

Authors: Wu, Yi-Long, Lu, Shun, Yang, James Chih-Hsin, Zhou, Jianying, Seto, Takashi, Ahn, Myung-Ju, Su, Wu-Chou, Yamamoto, Noboru, Kim, Dong-Wan, Paolini, Jolanda, Usari, Tiziana, Iadeluca, Laura, Wilner, Keith D., Goto, Koichi

Source: In JTO Clinical and Research Reports October 2022 3(10)

Improved survival in patients with unresectable stage III EGFR‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors

Authors: Wang, Sheng‐Yuan, Lai, Ching‐Han, Chen, Chian‐Wei, Yang, Szu‐Chun, Chang, Chao‐Chun, Lin, Chia‐Ying, Yen, Yi‐Ting, Tseng, Yau‐Lin, Su, Po‐Lan, Lin, Chien‐Chung, Su, Wu‐Chou

Source: Thoracic cancer. 13(2):182-189

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100139001596.0x000001&indx=1&recIds=ETOCvdc_100139001596.0x000001

Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non–small cell lung cancer

Authors: Santoro, Armando, Su, Wu-Chou, Navarro, Alejandro, Simonelli, Matteo, CH Yang, James, Ardizzoni, Andrea, Barlesi, Fabrice, Hyoung Kang, Jin, DiDominick, Sarah, Abdelhady, Ahmed, Chen, Xueying, Stammberger, Uz, Felip, Enriqueta

Source: Lung cancer. 166:170-177

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100164541753.0x000001&indx=1&recIds=ETOCvdc_100164541753.0x000001

A novel dielectrophoresis-based microfluidic chip for antibody-free isolation of circulating tumor cells from blood

Authors: Cheng, I-Fang, Chen, Tzu-Ying, Lin, Yu-De, Huang, Wei-Lung, Liu, Chien-Wei, Su, Wu-Chou

Source: 2015 IEEE 15th International Conference on Nanotechnology (IEEE-NANO) Nanotechnology (IEEE-NANO) , 2015 IEEE 15th International Conference on. :1525-1527 Jul, 2015

Relation: 2015 IEEE 15th International Conference on Nanotechnology (IEEE-NANO)

Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial

Authors: Lu, Shun, Wang, Qiming, Zhang, Guojun, Dong, Xiaorong, Yang, Cheng-Ta, Song, Yong, Chang, Gee-Chen, Lu, You, Pan, Hongming, Chiu, Chao-Hua, Wang, Zhehai, Feng, Jifeng, Zhou, Jianying, Xu, Xingxiang, Guo, Renhua, Chen, Jianhua, Yang, Haihua, Chen, Yuan, Yu, Zhuang, Shiah, Her-Shyong, Wang, Chin-Chou, Yang, Nong, Fang, Jian, Wang, Ping, Wang, Kai, Hu, Yanping, He, Jianxing, Wang, Ziping, Shi, Jianhua, Chen, Shaoshui, Wu, Qiong, Sun, Changan, Li, Chuan, Wei, Hongying, Cheng, Ying, Su, Wu-Chou, Hsia, Te-Chun, Cui, Jiuwei, Sun, Yuping, Ou, Sai-Hong Ignatius, Zhu, Viola W., Chih-Hsin Yang, James

Source: In Journal of Thoracic Oncology March 2022 17(3):411-422

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Authors: Herbst, Roy S., Garon, Edward B., Kim, Dong-Wan, Cho, Byoung Chul, Gervais, Radj, Perez-Gracia, Jose L., Han, Ji-Youn, Majem, Margarita, Forster, Martin D., Monnet, Isabelle, Novello, Silvia, Gubens, Matthew A., Boyer, Michael, Su, Wu-Chou, Samkari, Ayman, Jensen, Erin H., Kobie, Julie, Piperdi, Bilal, Baas, Paul

Source: In Journal of Thoracic Oncology October 2021 16(10):1718-1732

Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non–small-cell lung cancer: a multicenter study using targeted next-generation sequencing

Authors: Lin, Yen-Ting, Chiang, Chi-Lu, Hung, Jen-Yu, Lee, Mei-Hsuan, Su, Wu-Chou, Wu, Shang-Yin, Wei, Yu-Feng, Lee, Kang-Yun, Tseng, Yen-Han, Su, Jian, Chung, Hsin-Pei, Lin, Chih-Bin, Ku, Wen-Hui, Chiang, Tsai-Shin, Chiu, Chao-Hua, Shih, Jin-Yuan

Source: In European Journal of Cancer October 2021 156:1-11

EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis

Authors: Tsai, Jeng-Shiuan, Su, Po-Lan, Yang, Szu-Chun, Chang, Chao-Chun, Lin, Chia-Ying, Yen, Yi-Ting, Tseng, Yau-Lin, Lai, Wu-Wei, Lin, Chien-Chung, Su, Wu-Chou

Source: In Journal of the Formosan Medical Association September 2021 120(9):1729-1739

Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment

Authors: Su, Po-Lan, Tsai, Jeng-Shiuan, Yang, Szu-Chun, Wu, Yi-Lin, Tseng, Yau-Lin, Chang, Chao-Chun, Yen, Yi-Ting, Lin, Chia-Ying, Lin, Chien-Chung ^*, Wang, Chin-Chou ^**, Lin, Meng-Chih, Su, Wu-Chou

Source: In Lung Cancer August 2021 158:137-145

Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study

Authors: Yang, James Chih-Hsin, Reckamp, Karen L., Kim, Young-Chul, Novello, Silvia, Smit, Egbert F., Lee, Jong-Seok, Su, Wu-Chou, Akerley, Wallace L., Blakely, Collin M., Groen, Harry J.M., Bazhenova, Lyudmila, Carcereny Costa, Enric, Chiari, Rita, Hsia, Te-Chun, Golsorkhi, Tony, Despain, Darrin, Shih, Danny, Popat, Sanjay, Wakelee, Heather

Source: In JTO Clinical and Research Reports February 2021 2(2)